^
    3d
    CART123 + Ruxolitinib in Relapsed/Refractory AML (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, University of Pennsylvania | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    DNMT3A (DNA methyltransferase 1) • ASXL1 (ASXL Transcriptional Regulator 1) • TET2 (Tet Methylcytosine Dioxygenase 2)
    |
    ASXL1 mutation • TET2 mutation
    |
    Jakafi (ruxolitinib) • CART123
    5d
    Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis (clinicaltrials.gov)
    P1, N=3, Not yet recruiting, Novartis Pharmaceuticals
    New P1 trial
    |
    Jakafi (ruxolitinib) • pelabresib (DAK539)
    7d
    PRISM: Retifanlimab and Ruxolitinib In Solid Malignancies (clinicaltrials.gov)
    P1/2, N=40, Recruiting, University of California, San Diego | Not yet recruiting --> Recruiting
    Enrollment open • Checkpoint inhibition
    |
    PD-L1 (Programmed death ligand 1)
    |
    Jakafi (ruxolitinib) • Zynyz (retifanlimab-dlwr)
    8d
    Hypoxic conditions confer chemoresistance to crizotinib but not to imatinib in chronic myeloid leukemia cells. (PubMed, Hematol Transfus Cell Ther)
    In summary, this study shows the critical role of selective targeting of components of the HIF1α signaling pathway for the complete eradication of chronic myeloid leukemia cells.
    Journal
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit)
    |
    Xalkori (crizotinib) • imatinib • Jakafi (ruxolitinib) • Panzem (2-methoxyestradiol)
    11d
    Identifying targeted therapies for CBFA2T3::GLIS2 acute myeloid leukemia. (PubMed, Leukemia)
    Using a doxycycline-inducible JAK2 knockout (KO) system, we validated JAK2 dependency in CBFA2T3::GLIS2 cell lines, observing impaired proliferation in vitro and in vivo and apoptosis induction in vitro. Both type I (ruxolitinib) and type II (CHZ868) JAK2 inhibitors showed selective in vitro activity in CBFA2T3::GLIS2-positive AML models...Both approaches converged on MAPK pathway activation as a resistance mechanism to ruxolitinib treatment. Combining ruxolitinib with MEK inhibitors showed a synergistic effect in cell lines and patient-derived xenograft (PDX) cells expressing the fusion and in vivo activity in a CBFA2T3::GLIS2 AML PDX, suggesting a potential approach to target this signaling circuitry in this poor outcome AML subtype.
    Journal
    |
    NRAS (Neuroblastoma RAS viral oncogene homolog) • CBFA2T3 (CBFA2/RUNX1 Partner Transcriptional Co-Repressor 3) • GLIS2 (GLIS Family Zinc Finger 2)
    |
    NRAS mutation
    |
    Jakafi (ruxolitinib) • CHZ868
    12d
    Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma (clinicaltrials.gov)
    P2, N=83, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Nov 2025 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    JAK2 (Janus kinase 2)
    |
    Jakafi (ruxolitinib)
    12d
    Bioinformatics and experimental approaches identify NME8 as a promoter of the metastasis of renal cell carcinoma by activating the JAK/STAT signaling pathway. (PubMed, Clin Exp Med)
    Furthermore, exposure to the Janus kinase (JAK) inhibitor ruxolitinib and the signal transducer and activator of transcription (STAT)3 inhibitor stattic demonstrated that NME8 promoted RCC metastasis by activating the JAK/STAT signaling pathway...In conclusion, our findings suggest that NME8 contributes to RCC metastasis by promoting JAK/STAT-mediated EMT and modulating the tumor immune microenvironment. While elevated NME8 expression correlates with poor prognosis in public cohorts, its utility as a clinical prognostic biomarker requires further validation in independent patient populations.
    Journal
    |
    CDH1 (Cadherin 1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • VIM (Vimentin)
    |
    Jakafi (ruxolitinib)
    13d
    Inhibition of the JAK2/STAT3 Pathway Attenuates D-Galactose-Induced Nucleus Pulposus Cell Senescence and Intervertebral Disc Degeneration. (PubMed, Stem Cells Int)
    The model was then intervened with a JAK2/STAT3 pathway inhibitor (ruxolitinib) or JAK2-specific small interfering RNA (siRNA)...: Inhibition of the JAK2/STAT3 pathway reduced the expression of inflammatory factors and oxidative stress markers in D-gal-treated NPCs. It also suppressed ECM degradation and apoptosis, delayed cellular senescence, and attenuated the progression of IVDD in rats.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • IL1B (Interleukin 1, beta) • ACAN (Aggrecan) • MMP3 (Matrix metallopeptidase 3)
    |
    Jakafi (ruxolitinib)
    14d
    A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis (clinicaltrials.gov)
    P3, N=105, Not yet recruiting, Chengdu Zenitar Biomedical Technology Co., Ltd
    New P3 trial
    |
    Jakafi (ruxolitinib) • flonoltinib
    14d
    Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML) (clinicaltrials.gov)
    P1/2, N=66, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Jakafi (ruxolitinib) • Niktimvo (axatilimab-csfr)
    18d
    Ultraprecision Therapy for Type 1 vs Type 2 CALR+ MPN by Dual Epitope Targeting that Restores Ruxolitinib Sensitivity. (PubMed, Blood)
    In contrast, Type 2 mutations showed increased CALR dimerization and were partially resistant to antibody targeting but could be impacted by ruxolitinib triple combination. Together, our data demonstrate an ultra-precision medicine approach tailored to either Type 1 OR Type 2 mutation classes will be required for maximal efficacy and complete blockade of JAK/STAT signalling, with far-reaching implications for patient management.
    Journal • CALR
    |
    JAK2 (Janus kinase 2) • CALR (Calreticulin) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1)
    |
    CALR mutation
    |
    Jakafi (ruxolitinib)
    19d
    Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia (clinicaltrials.gov)
    P1/2, N=36, Not yet recruiting, M.D. Anderson Cancer Center
    New P1/2 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • Jakafi (ruxolitinib)